Search intent hub
Growth Hormone Secretagogues
CJC-1295, ipamorelin, sermorelin, and tesamorelin compared by mechanism, evidence, and regulatory status.
Concise answer
What searchers should know
Growth hormone secretagogues affect endocrine pathways. Evidence ranges from FDA-approved niche use to small biomarker studies and research-only compounds.
Guide note
Not one category
Tesamorelin has an FDA-approved product for a narrow indication. CJC-1295 and ipamorelin are investigational. Sermorelin has older clinical literature.
Guide note
Hormone-axis caution
GH and IGF-1 pathways affect many tissues. Medical history, cancer risk, glucose status, and pituitary function matter.
Guide note
Sport status
Growth hormone releasing factors and secretagogues are high-risk under anti-doping rules.
Profiles
Peptides in This Hub
CJC-1295
An investigational long-acting GHRH analog studied for growth hormone and IGF-1 signaling.
Ipamorelin
A selective growth hormone secretagogue studied in early human pharmacology and gastrointestinal motility contexts.
Sermorelin
A GHRH analog historically studied for growth hormone deficiency testing and pediatric growth contexts.
Tesamorelin
An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication.
Battles
Related Comparisons
Common Questions
Are GH secretagogues safer than growth hormone?
That broad claim is not supported. Different mechanisms do not remove the need for clinical oversight.
Do secretagogues build muscle?
PeptideWars does not treat biomarker changes as proof of muscle-building outcomes.